Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
3(60%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_3
4
80%
Ph phase_2
1
20%

Phase Distribution

0

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
4(80.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

5

all time

Status Distribution
Active(3)
Completed(2)

Detailed Status

Recruiting3
Completed2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
3
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (20.0%)
Phase 34 (80.0%)

Trials by Status

completed240%
recruiting360%

Recent Activity

3 active trials
Showing 5 of 5
recruitingphase_3

Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

NCT07484217
completedphase_3

A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)

NCT05972044
recruitingphase_3

Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)

NCT06568367
recruitingphase_3

Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol

NCT06413433
completedphase_2

A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults

NCT04839562

Clinical Trials (5)

Showing 5 of 5 trials
NCT07484217Phase 3

Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

Recruiting
NCT05972044Phase 3

A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)

Completed
NCT06568367Phase 3

Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)

Recruiting
NCT06413433Phase 3

Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol

Recruiting
NCT04839562Phase 2

A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5